UBS Group AG Sells 331,713 Shares of Rapport Therapeutics, Inc. $RAPP

UBS Group AG lowered its stake in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) by 59.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 226,360 shares of the company’s stock after selling 331,713 shares during the period. UBS Group AG’s holdings in Rapport Therapeutics were worth $6,868,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Capital International Investors boosted its holdings in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after buying an additional 800,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Rapport Therapeutics by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock valued at $55,151,000 after buying an additional 191,219 shares during the period. Baker BROS. Advisors LP grew its holdings in shares of Rapport Therapeutics by 181.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after buying an additional 997,000 shares during the period. Alliancebernstein L.P. increased its position in shares of Rapport Therapeutics by 4.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock valued at $13,129,000 after buying an additional 45,063 shares in the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at $28,215,000.

Insider Transactions at Rapport Therapeutics

In other news, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $40.32, for a total transaction of $17,176,521.60. Following the completion of the transaction, the insider directly owned 6,709,228 shares in the company, valued at $270,516,072.96. This represents a 5.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Cheryl Gault sold 2,014 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $28.93, for a total transaction of $58,265.02. Following the transaction, the chief operating officer owned 169,914 shares of the company’s stock, valued at approximately $4,915,612.02. This represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 878,600 shares of company stock worth $35,223,398 in the last three months. Insiders own 13.57% of the company’s stock.

Rapport Therapeutics Price Performance

Rapport Therapeutics stock opened at $34.37 on Wednesday. The firm has a 50-day moving average of $33.32 and a 200-day moving average of $29.95. Rapport Therapeutics, Inc. has a one year low of $7.73 and a one year high of $42.27. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -13.22 and a beta of 0.82.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.14. The business had revenue of $20.00 million for the quarter, compared to analyst estimates of $7.50 million. As a group, sell-side analysts expect that Rapport Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RAPP has been the subject of a number of recent analyst reports. Raymond James Financial initiated coverage on shares of Rapport Therapeutics in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $66.00 price objective for the company. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. Wells Fargo & Company upped their price objective on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.83.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.